Why It Happens
GLP-1 receptor agonists can slow gastric emptying and affect satiety pathways. Food may stay in the stomach longer, and fullness signals can become more noticeable. Large portions, high-fat meals, or eating quickly may make nausea more likely for some people, which is why GI-management guidance often focuses on meal size, fat content, and pace.
What the Trials Show
In Wegovy injection 2.4 mg adult weight-reduction trials, nausea was reported in 44% of semaglutide-treated adults versus 16% on placebo. In the pooled STEP 1-3 semaglutide 2.4 mg tolerability analysis, nausea was 43.9% versus 16.1%, the median nausea duration was 8 days, and first gastrointestinal adverse events plateaued after week 20. The Zepbound label reports nausea in 8% on placebo, 25% on 5 mg, 29% on 10 mg, and 28% on 15 mg, with most nausea, vomiting, and diarrhea events occurring during dose escalation and decreasing over time.
What this means
References4 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Human Trial
Massachusetts Medical SocietyOnce-Weekly Semaglutide in Adults with Overweight or Obesity Read source
Used Here ForGrounding the nausea question in the STEP 1 trial's adverse-event data.
Good ForTrial-measured nausea frequency with semaglutide 2.4 mg.
Not ForPredicting a specific person's nausea severity or duration.
New England Journal of Medicine 384(11):989-1002 - Official Label
FDA-approved prescribing information (Wegovy)
U.S. Food and Drug Administration / Novo NordiskWEGOVY (semaglutide) prescribing information: 6 Adverse Reactions Read source
Used Here ForChecking the nausea rates the approved label reports.
Good ForThe FDA-approved adverse-reaction rates from the weight-management trials.
Not ForPredicting a specific person's nausea severity or duration.
FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026 - Human Trial
Diabetes, Obesity and Metabolism
WileyGastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Read source
Used Here ForAdding the pooled STEP 1 to 3 analysis of nausea frequency and duration.
Good ForPooled trial data on the gastrointestinal tolerability of semaglutide 2.4 mg.
Not ForPredicting a specific person's nausea severity or duration.
Diabetes, Obesity and Metabolism 24(1):94-105 - Human TrialMassachusetts Medical Society
Tirzepatide Once Weekly for the Treatment of Obesity Read source
Used Here ForAdding the tirzepatide nausea rates from SURMOUNT-1.
Good ForTrial-measured gastrointestinal side effects of tirzepatide across doses.
Not ForPredicting a specific person's nausea severity or duration.
New England Journal of Medicine 387(3):205-216